Saturday, May 25, 2024
HomeHealthSurgical treatment of tuberous and tendinous xanthoma

Surgical treatment of tuberous and tendinous xanthoma


Introduction

Xanthomas are well-circumscribed exogenous masses, which mainly developed in soft tissue such as skin, tendons, joints, and fasciae. The clinical manifestations of xanthomas are variable, appear as yellow macules, papules, or large nodules. It is common to simply classify the xanthoma according to their location-skin or tendons. In the skin the xanthoma may take multiple forms: planar xanthomas, eruptive xanthoma, tubo-eruptive xanthoma, and tuberous xanthomata. In the tendons, the xanthomas called tendinous xanthomas.1,2 Among these, tuberous xanthomas are usually presented as flat or elevated plaques less than 2 centimeters in diameter, often found in patients with lipoprotein metabolic disorders.3,4 Here, we report a rare case of successful surgical treatment for multiple large tuberous and tendinous xanthomas secondary to familial hypercholesterolaemia (FH).

Case Report

A 17-year-old female patient presented to our hospital with complaints of multiple asymptomatic and papulo-nodular masses in different locations of the body, including palms, elbows, buttocks, knees, and Achilles tendons. The masses were of varying sizes, ranging from 0.3 cm to 8 cm (Figure 1). The patient complained of difficulty dressing and sitting due to unsightly and large masses. She reported a family history of hypercholesterolaemia and xanthoma for which his father also had two masses on both buttocks and received surgical removal at the age of 8. However, her mother had no history of xanthoma or hypercholesterolemia. Laboratory examinations showed marked abnormalities: serum cholesterol (Chl): 13.75 mmol/L (normal: <5.18 mmol/L); high-density lipoprotein cholesterol (HDL-C): 2.07 mmol/L (1.03–1.55 mmol/L); low-density lipoprotein cholesterol (LDL-C): 13.19 mmol/L (<3.37 mmol/l); small dense low-density lipoprotein cholesterol (sdLDL-C): 2.54 mmol/L (<0.9 mmol/L); apoprotein A1 (ApoA1): 1.03g/L (1.20–1.60 g/L); apoprotein B (ApoB): 2.61g/L (0.60–1.20 g/L); apoprotein A1/B (A1/B): 0.39 (1–2); apoprotein E (ApoE): 5.89 mg/mL (2.70–4.50 mg/mL); lipoprotein-associated phospholipaseA2 (Lp-PLA2): 1668U/L (≤535 U/L). The patient had no cardiac symptoms. The result of chest X-ray, electrocardiogram, echocardiogram, and abdominal ultrasound of the patient were normal. After admission, ultrasound produced inconclusive diagnosis and further MRI scan was applied. The masses revealed low signal intensity on T1-weighted images and low-high mixed signal intensity on T2-weighted images. (Figure 2). Based on the Simon Broome criteria, the patient was diagnosed with Familial hypercholesterolemia (FH). Unfortunately, the patient refused to receive genetic testing.

CCID A 445163 O F0001g Thumb

Figure 1 Multiple subcutaneous lesions over different locations. (A and B) lesions in both elbows. (C) lesions in both knees. (D) lesions in buttocks. (E) lesions in Achilles tendons. (F) lesions over proximal interphalangeal joints.

CCID A 445163 O F0002g Thumb

Figure 2 MRI imaging of xanthomas masses on left (A and B) and right (C and D) elbows. The masses revealed low signal intensity on T1-weighted images and low-high mixed signal intensity on T2-weighted images.

The patient then received surgical treatment to remove the masses. The masses on both elbows, buttocks, and knees were removed completely through W-shaped incisions. Masses on palms and Achilles tendons were not removed because these masses were small, and the patient had to walk to school in a few days. The surfaces of resected masses were normal skin. The cores of masses were yellowish-colored, relatively soft, no necrosis, and confined to the subcutaneous tissue without involving underlying muscle or joint capsule (Figure 3). Histopathology showed infiltration of foam cells and scattered giant cells with lipid-rich background (Figure 4). After removal, all incisions were sutured carefully (Figure 5). The patient was discharged at 5 days postoperatively, and all sutures were removed 14 days after operation without any complications. The patient had not been treated for this disease before, for the management of cholesterol, she received oral atorvastatin 40 mg once per day. A following up of 3 months showed all wounds were healing well, and no recurrence of masses was observed.

CCID A 445163 O F0003g Thumb

Figure 3 Intraoperative photograph of the lesions. (A and B) Resected xanthomas. (C) The sectional view of the xanthomas.

CCID A 445163 O F0004g Thumb

Figure 4 Pathological pictures of the lesion. (A) Hematoxylin/eosin analysis showed infiltration of foamy cells and scattered giant cells (x200). CD68-immunostaining (B), Ki67- immunostaining (C) and TFE3- immunostaining (D) of the xanthomas presented positive (x200).

CCID A 445163 O F0005g Thumb

Figure 5 Status of the incisions two days after the operation. (A and B) elbows. (C) buttocks. (D) knees.

Discussion

Xanthomas are masses that are characterized by the clusters of foam cells, which are formed from lipid-filled macrophages within deep soft tissue.2 The development of xanthoma begins with an increased permeation of lipids to the connective tissue interspace through the vascular wall. Macrophages accumulated there phagocytize the excessive low-density lipoprotein (LDL) particles. As a result, foam cells can be formed.

FH is an inherited autosomal dominant disorder with a raised LDL plasma level, so patients with FH have a high risk of xanthomas.5 In this case, no obvious diseases affecting lipid metabolism such as liver and kidney diseases and diabetes were found by routine examination, and blood lipid tests showed significant increases in serum cholesterol, especially LDL level. In addition, the patient reported that her grandfather and father also had hypercholesterolemia. Furthermore, her father had two masses on both buttocks and received surgical removal at the age of 8. However, her mother had no history of xanthoma or hypercholesterolemia. According to the diagnostic criteria of Homozygous familial hypercholesterolaemia (HoFH),6,7 a clinical diagnosis of HoFH rather than heterozygous familial hypercholesterolaemia (HeFH) for this patient can be made on the basis of skin or tendon xanthomas since infancy, and untreated LDL-C levels of 13.19 mmol/L(>500mg/dL), four times higher than normal levels.

As previously stated, xanthomas are typically less than 2 centimeters in diameter and occurred most frequently at extensor surfaces due to mechanical stresses, such as knuckles, elbows, knees, and buttocks.8 Therefore, the occurrence of our patient with multiple large xanthomas is rare. In our case, the masses grow to be large, entangled, and quite influence the patient’s activities and life quality. This is the main reason for the patient to seek medical care.

For patients with xanthomas, lipid-lowering therapy is necessary for reducing the size of masses and decreasing cardiovascular complications.9,10 In this case, the patient was started on atorvastatin 40mg/day immediately after admission. For large xanthomas caused pain or limitation of daily activities, surgical intervention is required. However, for use in the treatment of HoFH, additional therapy with PCSK9 Inhibitors also plays an important role. PCSK9 protein plays an important role in post-translational regulation of LDL- Receptor, and inhibition of pcsk9 protein can lead to upregulation of LDL- Receptor, resulting in greater LDL-C clearance. PCKS9 monoclonal antibodies such as evolocumab are effective in reducing LDL-C in patients with HoFH. PCSK9 inhibition can also be achieved with small interfering RNA therapy, and inclisiran is the first approved therapy of its kind.11,12 Lowering LDL-C can also be achieved by using drugs such as lomitapide, which inhibits microsomal triglyceride transfer proteins, thereby reducing LDL synthesis.13

Similar to other tumor surgery, en bloc resection of the masses plays an important role clinically in preventing postoperative local recurrence. Meanwhile, as plastic surgeons, we are committed to achieving satisfying cosmetic effect. Appropriate skin flaps will be selected to repair the wound after resection, and all incisions are closed without tension. In this case, a following up of 3 months showed all wounds were healing well with slight scar or no scar formed, and no recurrence of masses was observed.

Conclusion

For patients with xanthomas related with familial hypercholesterolaemia, early diagnosis and treatment are of great importance, which will reduce the occurrence of cardiovascular complications. Surgical treatment is essential for large xanthomas caused pain or limitation of daily activities. However, for patients with FH, especially HoFH, initiation of aggressive LDL-C lowering as early as possible is essential for preventing their premature deaths.

Ethics Statement

No institutional approval is required for case reports, and the patient cannot be identified from the images.

Informed Consent Statement

Patient and her parents consented in writing for the publication of her case/photographs both online and in-print and understood that it will be publicly available and was sent a copy of the article to read.

Funding

This study was supported by Shanghai Clinical Research Center of Plastic and Reconstructive Surgery supported by Science and Technology Commission of Shanghai Municipality (Grant No. 22MC1940300).

Disclosure

The authors report no conflicts of interest in this work.

References

1. Tummidi S, Kothari K, Rojekar A, et al. Multiple tuberous and tendinous xanthomas diagnosed on fine-needle aspiration cytology-report of a rare case. Diagn Cytopathol. 2019;47(9):939–942. doi:10.1002/dc.24219

2. Zak A, Zeman M, Slaby A, et al. Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(2):181–188. doi:10.5507/bp.2014.016

3. Aljenedil S, Ruel I, Watters K, et al. Severe xanthomatosis in heterozygous familial hypercholesterolemia. J Clin Lipidol. 2018;12(4):872–877. doi:10.1016/j.jacl.2018.03.087

4. Ribeiro RM, Vasconcelos SC, Lima P, et al. Pathophysiology and treatment of lipid abnormalities in cerebrotendinous xanthomatosis: an integrative review. Brain Sci. 2023;13(7):979. doi:10.3390/brainsci13070979

5. Sato A, Tsukiyama T, Komeno M, et al. Generation of a familial hypercholesterolemia model in non-human primate. Sci Rep. 2023;13(1):15649. doi:10.1038/s41598-023-42763-1

6. Harada-Shiba M, Arai H, Ishigaki Y, et al; Yokote K and Working Group by Japan Atherosclerosis Society for Making Guidance of Familial H. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25(8):751–770. doi:10.5551/jat.CR003

7. Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolemia. Nat Rev Dis Primers. 2017;3(1):17093. doi:10.1038/nrdp.2017.93

8. Dung PTV, Son TT, Thuy TTH, et al. Surgical treatment of multiple large tuberous xanthomas in familial hypercholesterolemia: a case report. Int J Surg Case Rep. 2021;89:106596. doi:10.1016/j.ijscr.2021.106596

9. Zha S, Yu X, Wang X, et al. Topical simvastatin improves lesions of diffuse normolipemic plane xanthoma by inhibiting foam cell pyroptosis. Front Immunol. 2022;13:865704. doi:10.3389/fimmu.2022.865704

10. Thadchanamoorthy V, Dayasiri K, Majitha SI, et al. Homozygous autosomal recessive hypercholesterolaemia in a South Asian child presenting with multiple cutaneous xanthomata. Ann Clin Biochem. 2021;58(2):153–156. doi:10.1177/0004563220961755

11. Arca M, Celant S, Olimpieri PP, et al. Real-world effectiveness of PCSK9 inhibitors in reducing LDL-C in patients with familial hypercholesterolemia in Italy: a retrospective cohort study based on the AIFA Monitoring Registries. J Am Heart Assoc. 2023;12(21):e026550. doi:10.1161/JAHA.122.026550

12. Raal F, Durst R, Bi R, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2024;149(5):354–362. doi:10.1161/CIRCULATIONAHA.122.063460

13. Nohara A, Tada H, Ogura M, et al. Homozygous Familial Hypercholesterolemia. J Atheroscler Thromb. 2021;28(7):665–678. doi:10.5551/jat.RV17050





Source link

RELATED ARTICLES

Leave a reply

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments